Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Maturitas
- Cardiovascular health and disease in women.N. Engl. J. Med. 1993; 329: 247-256
- Menopause and risk factors for coronary heart disease.N. Engl. J. Med. 1989; 321: 641-646
- Influence of menopause on serum lipids and lipoproteins.Maturitas. 1990; 12: 321-331
- Coronary heart disease risk factors in relation to the menopause.Q. J. Med. 1992; 85: 889-896
- Effects of age and menopause on lipid metabolism in healthy women.Atherosclerosis. 1993; 98: 83-90
- Lipids and lipoproteins in women after oophorectomy and the response to oestrogen therapy.Br. J. Obstet. Gynaecol. 1983; 90: 171-177
- Some atherogenic concomitans of menopause: the Framingham study.Am. J. Epidemiol. 1976; 103: 304-311
- Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women.J. Clin. Endocrinol. Metab. 1988; 67: 30-35
LaRosa JC. Women, lipoproteins and cardiovascular disease risk. Can J Cardiol 1990;(Suppl B):23B–9B.
- Incidence of coronary heart disease and lipoprotein cholesterol levels.JAMA. 1986; 256: 2835-2838
- Serum lipids and lipoproteins as predictors of atherosclerosis.Arteriosclerosis. 1989; 9: 560-564
- The triglyceride issue: a view from Framingham.Am. Heart J. 1986; 112: 432-437
Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199–208.
- Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000.Fertil. Steril. 2001; 75: 898-915
- Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence.Prev. Med. 1991; 20: 47-63
- Hormone therapy to prevent disease and prolong life in postmenopausal women.Ann. Intern. Med. 1992; 117: 1016-1037
- Patient-specific decisions about hormone replacement therapy in postmenopausal women.JAMA. 1997; 277: 1140-1147
- A prospective study of postmenopausal estrogen therapy and coronary heart disease.N. Engl. J. Med. 1985; 313: 1044-1049
- Use of replacement estrogens and the risk of myocardial infarction.Epidemiology. 1990; 1: 128-133
American College of Physicians. Guidelines for counselling postenopausal women about preventive hormone therapy. Am Intern Med 1992;117:1038–41.
Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopusal estrogen therapy. A report from the Boston Collaborative Drug Surveillance Program. Boston University Medical Center. N Engl J Med 1974;290:15–9.
Collaborative Group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy; collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047–59.
- Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.JAMA. 1998; 380: 605-613
- Effects of estrogen replacement on the progression of coronary-artery atherosclerosis.N. Engl. J. Med. 2000; 343: 522-529
- Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens.J. Clin. Endocrinol. Metab. 2001; 86: 41-47
- What role can diet play in the increased risk of cardiovascular disease in women aged 40 years and over?.Med. J. Aust. 2000; 173: S101-S102
- Soy proteins and cardiovascular disease.Curr. Atheroscler. Rep. 2001; 3: 47-53
Cassidy A, Bingham S, Setchell K. Biological effects of isoflavones in young women: importance of the chemical composition of soybean products.
- A review of the evidence for the use of phytoetrogens as a replacement for traditional estrogen replacement therapy.Arch. Intern. Med. 2001; 161: 1161-1172
- Soy isoflavone improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women.Arteriosler. Thromb. Vasc. Biol. 1997; 17: 3392-3398
- Intact dietary soy protein, but not adding an isoflavone-rich soy extract to casein improves plasma lipids in ovariectomized cynomolgus monkeys.J. Nutr. 1999; 129: 1585-1592
- Phytoestrogens as therapeutic alternatives to traditional hormone replacement in postmenopausal women.Pharmacotherapy. 2000; 20: 981-990
- Reducing bioavaible sex hormones through a comprehensive change in diet: the diet and androgens (DIANA) randomised trial.Cancer Epidemiol Biomarkers Prev. 2001; 10: 25-33
- Postmenopausal hormone therapy: less favourable risk-benefit ratios in healthy Dutch women.J. Intern. Med. 2000; 248: 143-150
- Postmenopausal hormone therapy and risk of stroke: the heart and Estrogen-progestin Replacement Study (HERS).Circulation. 2001; 103: 638-642
- Meta-analysis of the effects of soy protein intake on serum lipids.N. Engl. J. Med. 1995; 333: 276-282
The role of Isoflavones in menopausal health: consensus opinion of the North American Menopause Society. (without authors) Menoapause 2000;7(4):215–229.
- Association of soy and fiber consumption with the risk of endometrial cancer.Am. J. Epidemiol. 1997; 146: 294-306